U.S. Patent Disclosures

August 2011
BioWorld Today;8/15/2011, Vol. 22 Issue 157, p4
The article announces the granting of U.S. patents for biotechnology firms in 2011. Alethia Biotherapeutics Inc. received a patent for "Polynucleotide and Polypeptide Sequences Involved in the Process of Bone Remodeling." Convergen LifeSciences was given a patent for the CNVN202 targeted molecular cancer therapy. Hemispherx Biopharma Inc. received a patent for the seasonal influenza vaccine Ampligen.


Related Articles

  • HEMISPHERX COMPLETES ENROLLMENT IN PHASE II AMPLIGEN STUDY.  // Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p8 

    The article reports the start of Phase II clinical trial of Ampligen (r) as seasonal flue vaccine enhancer has been completed by Hemispherx Biopharma Inc. in Australia. The company will evaluate the safety and efficacy of Ampligen (r) as an enhanser for seasonal flu vaccine. The secondary goal...

  • HEMISPHERX INITIATES AMPLIGEN PHASE IIB FOR INFLUENZA.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p2 

    The article reports that the Ampligen Phase IIB trial for influenza was initiated by the Hemispherx Biopharma, Inc. in Australia. The Japanese National Institute of Infectious Diseases (JIID) reported robust immune responses in animals when Ampligen (r) was added to either avian or seasonal...

  • CLINIC ROUNDUP.  // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p12 

    This section offers news briefs on clinical trials of various drugs as of June 2008. AMAG Pharmaceuticals Inc. reported positive results from two Phase III studies of ferumoxytol as iron replacement therapeutic agent in patients with chronic kidney disease with functioning kidney transplants....

  • U.S. Patent Disclosures.  // BioWorld Today;12/16/2011, Vol. 22 Issue 242, p4 

    This section offers news briefs related to U.S. patent disclosures, including the patent granted to Advaxis Inc., Alethia Biotherapeutics Inc. and Allon Therapeutics Inc.

  • Clinic Roundup.  // BioWorld Today;3/20/2012, Vol. 23 Issue 44, p8 

    The article reports that Hemispherx Biopharma Inc. published the results of a Phase III trial of Ampligen in chronic fatigue in "PLoS ONE."

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • Alethia, Canadian Agency In Cancer Targeting Deal.  // Bioworld Week;10/8/2007, Vol. 15 Issue 41, p4 

    The article reports on the agreement of between Alethia Biotherapeutics Inc. and National Research Council Biotechnology Research Institute. The initiative aims to acquire worldwide therapeutic and diagnostic rights to Clusterin-specific antibodies. Under the agreement, Alethia gains access to...

  • Phase I Clinical Trials Update: August 2011.  // BioWorld Insight;9/12/2011, Vol. 19 Issue 37, p7 

    A chart is presented that lists the company, products, and product description of various drugs from the Phase I Clinical Trials Update for August 2011 including the oral antiandrogenic APC-100 from Adamis Pharmaceuticals Corp., the ALN-VSP from Alnylam Pharmaceuticals Inc., and the Ampligen, a...

  • AACR Roundup.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8 

    The article focuses on the preclinical data presented by Hemispherx Biopharma Inc. at the annual meeting of the American Association for Cancer Research (AACR) on the adjuvant effect of Ampligen in a transgenic mouse breast cancer model.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics